Journal
CANCER LETTERS
Volume 285, Issue 2, Pages 166-173Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.05.011
Keywords
Piceatannol; Cell cycle progression; Cyclin-dependent kinase
Categories
Funding
- Korean government (Ministry of Education, Science and Technology) [R01-2007-000-20164-0, 2009-0063409]
- National Research Foundation of Korea [R01-2007-000-20164-0] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
We have examined whether and by what mechanism piceatannol inhibits cell cycle progression in DU145 cells. The treatment of cells with piceatannol for 24 h resulted in an increase in the percentage of cells in G1 phase and dose-dependent decreases in [H-3]thymidine incorporation, as well as in protein levels of cyclin A, cyclin D1, and cyclin-dependent kinase (CDK)2 and CDK4. Piceatannol exerted no effect on the levels of p21(WAF1/CIP1) or p27(KIP1). Piceatannol reduced CDK4 and CDK2 activity. These results indicate that delaying G1 cell cycle progression contributes to the piceatannol-mediated inhibition of DU145 cell growth, which may be mediated via the inhibition of CDK activity. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available